Video

Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer

Author(s):

Sarah Sciortino, MSW, LSW
Conference|Ovarian Cancer National Conference

Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.

Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face. Decisions about fertility often have to be made quickly, and at a much earlier time than patients are prepared for. Additionally, body image and sexuality can be affected dramatically by treatment.

Related Videos
Kate, Princess of Wales, ‘Got So Attached’ to Her Port During Cancer Treatment
Dr. Michael Bogenschutz
Dr. Stephanie Alice Baker
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Image of woman with dark hair, smiling.
Related Content
Illustration of woman with blonde hair.
January 14th 2025

The Waiting Room: An Underappreciated Experience

Mary Sansone
As a cancer treatment waiting room volunteer, I’ve discovered a unique community of shared experiences and unexpected connections.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of female reproductive system.
January 13th 2025

HIPEC May Not Improve Outcomes for Recurrent Epithelial Ovarian Cancer

Spencer Feldman
Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
The FDA has accepted an NDA for avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.
January 2nd 2025

FDA Accepts NDA for Avutometinib Plus Defactinib in KRAS+ Low-Grade Serous Ovarian Cancer

Ryan Scott
An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer.
Illustration of woman with brown curly hair.
January 2nd 2025

Survivor’s Guilt: Asking, ‘Why Me?’

Karen Cohn
Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not.